medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2022, Number 1

<< Back Next >>

VacciMonitor 2022; 31 (1)

Emergency evaluation for existing vaccine against recently isolated Foot and mouth disease virus type SAT2 in Egypt 2018

Abousenna MS

Language: Spanish
References: 25
Page: 9-14
PDF size: 285.90 Kb.


ABSTRACT

Foot and mouth disease virus is a highly infectious and contagious pathogen. Recently the topotype VII, Lib‐12 lineage of serotype SAT2 was reported through outbreaks in Egypt during 2018. Vaccination is an effective way to control and combat the foot and mouth disease virus outbreaks especially in endemic areas like Egypt. The present study was aimed to evaluate the efficacy of the current produced foot and mouth disease vaccine, against the recently isolated field strain foot and mouth disease virus SAT2 topotype VII, Lib-12 lineage (SAT2 Libya), by applying in vitro and in vivo studies. Two batches of the current foot and mouth disease virus vaccine were inoculated in calves. At the 28th day post-vaccination serum samples were collected and tested against tissue culture adapted foot and mouth disease virus SAT2 Libya and SAT2/EGY/2/2012 using virus neutralization test to determine serological relationship (r1-value). The challenge test for vaccinated calves was carried out against the virulent foot and mouth disease virus SAT2 Libya. It was found that neutralizing antibody titers induced by the two vaccine batches (1 and 2) and those in unvaccinated animals were 0.48, 0.39 and 0.15 log10 TCID50/mL, respectively, while the challenge revealed protection values of 20%, 0% and 0%, respectively. Furthermore, the r1 values were 0.195 and 0.186 for vaccine batches (1 and 2), respectively. It was concluded that the available local commercial inactivated foot and mouth disease virus vaccine batches (SAT2 SAT2/EGY/2/2012) are unable to protect calves against the current circulating foot and mouth disease virus field isolate SAT2 topotype VII, Lib-12 lineage, thus it is highly recommended to update the existing vaccines with the present isolated strain.


REFERENCES

  1. Knight-Jones TJD, Rushton J. The economic impacts of foot and mouth disease-what are they, how big are they and where do they occur? Prev Vet Med. 2013;112(3-4):162-73.

  2. Grubman MJ, Baxt B. Foot-and-mouth disease. Clin Microbiol Rev. 2004; 17 (2): 465-93.

  3. Alexandersen S, Zhang Z, Donaldson AI, Garland AJ. The pathogenesis and diagnosis of foot-and-mouth disease. J Comp Pathol. 2003;129(1):1-36.

  4. Arzt J, Juleff N, Zhang Z, Rodríguez LL. The Pathogenesis of Foot-and-Mouth Disease I: Viral Pathways in Cattle. Transbound Emerg Dis. 2011;58: 291-304.

  5. Knowles NJ, Wadsworth J, Reid SM, Swabey KG, El-Kholy AA, El-Rahmanet AOA, et al. Foot-and-mouth disease virus serotype A in Egypt. Emerg Infect Dis. 2007;13(10):1593-6.

  6. Sobhy NM, Mor SK, Mohammed MEM, Bastawecy IM, Fakhry HM, Youssef CRB, et al. Phylogenetic analysis of Egyptian foot and mouth disease virus endemic strains. J Am Sci. 2014:10:133-8.

  7. Valdazo-González B, Knowles NJ, Hammond J, King DP. Genome sequences of SAT 2 foot-and-mouth disease viruses from Egypt and Palestinian Autonomous Territories (Gaza Strip). J Virol. 2012;86(16):8901-2.

  8. Soltan MA, Dohreig RMA, Abbas H, Ellawa M, Yousif I, Aly AE, et al. Emergence of Foot and mouth disease virus, Lib 12 lineage of topotype VII, serotype SAT2 in Egypt, 2018. Transbound Emerg Dis. 2019; 66:1105-6. doi: https://10.1111/tbed.13152.

  9. Hagag NM, Hamdy ME, Sargious MA, Elnomrosy SM, Ahmed NA, Hamed AA, et al. Molecular and genetic characterization of newly circulating foot and mouth disease virus (FMDV) serotype SAT2 in Egypt during 2018 and early 2019. Hosts and Viruses.2020; 6(5): 103-8.doi: https://10.17582/journal.hv/2019/6.5.103.108.

  10. Abousenna MS, Khafagy HA, Abotaleb MM, Darwish DM, Barghooth WM, Shafik NG. Alternative method for the evaluation of monovalent inactivated foot and mouth disease virus vaccine. VacciMonitor. 2021: 30(1):4-9. Available at: https://vaccimonitor.finlay.edu.cu/index.php/vaccimonitor/article/view/244.

  11. OIE. Organization for Animal Health. Foot and Mouth Disease (infection with foot and mouth disease). In: OIE. World Organization for Animal Health. Manual of diagnostic tests and vaccines for terrestrial animals (mammals, birds, bees). Paris: OIE; 2021. p. 1-31. Available at: https://www.oie.int/.

  12. Ferreira ME. Microtiter neutralization test for the study of foot-and-mouth disease antibodies. Boletin Centro Pan Americano de Fiebre Aftosa. 1976; 21(22): 17-20.

  13. Dekker A, van Hemert-Kluitenberg F, Oosterbaan AH, Moonen K, Mouton L. Replacement of foot-and-mouth disease virus cattle tongue titration by in vitro titration. ALTEX. 2018;35(4):489-94. doi: https://10.14573/altex.1712222.

  14. Kärber G.Contribution to the collective treatment of pharmacological series experiments. Arch Exp Pathol Pharmacol. 1931; 162: 480-3.

  15. Nermeen SG, Darwish DM, Abousenna MS, Galal M, Ahmed AR, Attya M, et al. Efficacy of a commercial local trivalent Foot and Mouth Disease (FMD) vaccine against recently isolated O-EA3. Inter J Vet Sci.2019;8(1): 35-8. Available from: https://www.ijvets.com/pdf-files/volume-8-no-1-2019/35-38pdf.

  16. Kitching RP, Rendle R, Ferris NP. Rapid correlation between field isolates and vaccine strains of foot-and-mouth disease virus. Vaccine.1988;6(5):403-8.

  17. Maree F, Kasanga C, Scott K, Opperman P, Chitray M, Sangula A, et al. Challenges and prospects for the control of foot-and-mouth disease: an African perspective. Vet Med (Auckl). 2014;5:119-38.

  18. Balinda SN, Sangula AK, Heller R, Muwanika VB, Belsham GJ, Masembe C, et al. Diversity and transboundary mobility of serotype O foot-and-mouth disease virus in East Africa: implications for vaccination policies. Infect Genet Evol. 2010;10(7):1058-65.

  19. Wekesa SN, Muwanika VB, Siegismund HR, Sangula AK, Namatovu A, Dhikusooka MT, et al. Analysis of Recent Serotype O Foot-and-Mouth Disease Viruses from Livestock in Kenya: Evidence of Four Independently Evolving Lineages. Transbound Emerg Dis. 2015;62(3):305-14. https://doi.org/10.1111/tbed.12152.

  20. Kerfua SD, Shirima G, Kusiluka L, Ayebazibwe C, Martin E, Arinaitwe E, et al. Low topotype diversity of recent foot-and-mouth disease virus serotypes O and A from districts located along the Uganda and Tanzania border. J Vet Sci. 2019;20(2):e4. https://doi.org/10.4142/jvs.2019.20.e4

  21. Jo HE, You SH, Choi JH, Ko MK, Shin SH, Song J, et al. Evaluation of novel inactivated vaccines for the SAT 1, SAT 2 and SAT 3 serotypes of foot-and-mouth disease in pigs. Virol J. 2019;16(1):156. doi:https://10.1186/s12985-019-1262-1.

  22. Rweyemamu MM. Antigenic variation in foot-and-mouth disease: studies based on the virus neutralization reaction. J Biol Stand.1984;12(3):323-37.

  23. Willems T, De Vleeschauwer A, Perez-Filgueira M, Li Y, Ludi A, Lefebvre D, et al. FMD vaccine matching: Inter laboratory study for improved understanding of r1 values. J Virol Methods.2020;276:113786. doi: https:/10.1016/j.jviromet.2019.113786.

  24. Blignaut B, van Heerden J, Reininghaus B, Fosgate GT, Heath L. Characterization of SAT2 foot-and-mouth disease 2013/2014 outbreak viruses at the wildlife-livestock interface in South Africa. Transbound Emerg Dis. 2020; 67(4): 1595-1606. doi:https://10.1111/tbed.13493.

  25. Leon EA, Perez AM, Stevenson MA, Robolio B, Mattion NM, Seki C, et al. Effectiveness of systematic foot and mouth disease mass vaccination campaigns in Argentina. Rev Sci Tech. 2014;33(3):917-26.




2020     |     www.medigraphic.com